- Open Access
MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist
© Sun et al. 2016
- Received: 27 October 2015
- Accepted: 8 January 2016
- Published: 13 January 2016
MicroRNAs (miRNAs) are a class of small non-coding RNAs, which post-transcriptionally repress the expression of genes involved in cancer initiation and progression. Although some miRNAs that target many signaling pathways (also called universe miRNAs) are supposed to play a global role in diverse human tumors, their regulatory functions in gynecological cancers remain largely unknown. We investigated the biological role and underlying mechanism of miR-548c (one universe miRNA) in endometrial and ovarian cancer.
The effects of miR-548c overexpression on cell proliferation, migration and invasion were studied in endometrial and ovarian cancer cells. TWIST1 (Twist) was identified as a direct miR-548c target by western blot analysis and luciferase activity assay. The expression of miR-548c and Twist were examined by qRT-PCR in endometrial and ovarian cancer tissues.
Here, we report that miR-548c is down-regulated in endometrial and ovarian cancer tissues when compared to normal tissues, and our meta-analysis reveal that decreased miR-548c expression correlates with poor prognosis in endometrial cancer patients. We show that in endometrial and ovarian cancer cells, ectopic expression of miR-548c significantly inhibits whereas knockdown of miR-548c dramatically induces cancer cell proliferation, migration and invasion. By using luciferase reporter assay, we demonstrate that Twist, a known oncogene in endometrial and ovarian cancers, is a direct target of miR-548c. Furthermore, the expression of Twist partially abrogates the tumor suppressive effects of miR-548c on cell migration and invasion.
These findings suggest that miR-548c directly downregulates Twist, and provide a novel mechanism for Twist upregulation in both endometrial and ovarian cancers. The use of miR-548c may hold therapeutic potential for the treatment of Twist-overexpressing tumors.
- Endometrial cancer
- Ovarian cancer
Metastasis is the main cause of death among patients with endometrial cancer (EC, the most frequently diagnosed gynecologic malignancy) cbl1, 2] and ovarian cancer (OC, the most lethal gynecological cancer) . The initial steps of metastasis include the detachment and migration of cancer cells and subsequent invasion into surrounding tissues . Epithelial-to-mesenchymal transition (EMT) is considered a key step in metastasis of endometrial and ovarian cancer [1, 5, 6], which enhances the migratory and invasive capacity of tumor cells to facilitate malignant progression. Therefore, understanding the molecular mechanisms that mediate migration, invasion and EMT process of EC and OC cells could identify novel molecular targets for future treatments of these cancers.
Twist1 (Twist) is a critical oncogene that is overexpressed and plays important roles in EMT induction in EC and OC [1, 7, 8]. High Twist expression positively correlated with deep myometrial invasion and poor outcome in EC . Aberrant expression of Twist in OC correlated with advanced tumor stage and predicted a poor clinical outcome [10, 11]. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that regulate gene expression via interactions with the 3’-untranslated regions (UTRs) of mRNAs targets, causing translational suppression or mRNA decay. MiRNAs control metastatic progression [12, 13], and act as either tumor suppressors or oncogenes in EC and OC [1, 14]. Although a number of miRNAs, such as miR-106b and miR-543, have been reported to suppress the expression of Twist and EC cell invasion [15, 16], miRNAs affecting Twist expression in EC and OC is still not completely understood. Recently, two distinct classes of microRNAs: universe miRNAs (for example, miR-34a) that regulate many signaling pathways, as well as intra-pathway miRNAs that target multiple genes within a single signaling pathway, have been identified . Universe microRNAs are predicted to affect more targets/signaling pathways, and might play a global role in tumor cells . Of interest, several universe miRNAs (including miR-548a/b/c, etc.) belong to the same miR-548 family  and have been implicated in tumorigenesis [18, 19], however their regulatory functions in gynecological cancers remain largely unknown.
In this study, we investigated the biological functions and underlying mechanism of miR-548c in EC and OC, and provide in vitro evidence that miR-548c inhibits migration and invasion in both EC and OC cells by directly targeting Twist. We further demonstrate that miR-548c expression inversely correlates with Twist expression in EC and OC tissues and the downregulation of miR-548c is associated with poor prognosis in EC patients.
Cell culture and transient transfection
The human EC cell lines (RL95-2 and HEC-1) and human OC cell lines (SKOV-3 and OVCAR3) were obtained from Chinese Academy of Sciences Committee on Type Culture Collection Cell Bank, Shanghai, China. These cells were cultured in DMEM/F12 medium (Invitrogen, Shanghai) or PRMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10 % fetal bovine serum (FBS, Invitrogen, Shanghai). MiR-548c mimic (40 nM), antisense miR-548c inhibitor (40 nM), Twist siRNA (5 nM) and respective negative controls were purchased from Ambion (TX, USA), and were transfected using Lipofectamine 2000 (Invitrogen, CA, USA), according to the manufacturer’s instructions. Transient transfection of Twist cDNA plasmids (OriGene, MD, USA) were performed with Lipofectamine Plus reagent (Invitrogen, CA, USA) according to the manufacturer’s protocol.
RNA extraction and real-time qRT-PCR
Total RNA was extracted using TRIzol reagents (Invitrogen, CA, USA). The miRNA qRT-PCR was performed using the NCode miRNA qRT-PCR analysis (Invitrogen, CA, USA). Forward primers for miRNA detection are the exact sequence of mature miR-548c-3p. For mRNA analysis, RT reaction was carried out using 100 ng total RNA with the PrimeScript RT reagent kit (Takara, Japan). Real-time qRT-PCR was performed using the Takara SYBR Premix Ex Taq II (Takara, Japan). Primers used for the amplification of E-cadherin , N-cadherin , CD133 , MMP-9  and GAPDH  have been previously described. All miRNA and mRNA quantification data were normalized to GAPDH. Results were given as the fold change relative to controls.
Cell proliferation assay and apoptosis assay
To evaluate cell proliferation, 5 × 103 cells were plated in 96-well plates for 24 h, and then transfected with miRNA mimic/inhibitor with or without Twist siRNA or Twist cDNA vector. At 72 h, cell proliferation was determined by the Cell Counting Kit-8 (Dojindo, Japan). The absorbance was determined at 450 nm using a microplate reader, and data were expressed as the percentage of absorbance relative to controls. For cell apoptosis assay, cells were transfected for 72 h and apoptotic cells were identified using the DeadEnd Colorimetric TUNEL System kit (Promega, WI, USA), following the manufacturer’s instructions. Cell apoptosis was quantified as the numbers of apoptotic cells found in 15 random fields. The ratio of dead/total cell number was calculated.
Cell migration and invasion assay
Cells were transfected for 24 h and then seeded into upper chamber of Boyden chambers coated with or without Matrigel as described previously [23–25]. After incubation for 24 h, migration and invasion were stained and counted under a light microscope. Relative migration and invasion activities were expressed as the fold change over respective controls.
Cells were harvested 48 h after transfections. Whole-cell protein extracts were prepared using the M-Per Mammalian Protein Extraction Reagent (Pierce Biotechnology, MA, USA) according to the manufacturer’s instructions. Total proteins (40 μg) were loaded onto 10 % SDS-PAGE for immunoblots with antibodies to Twist (Abcam, ab50887) and GAPDH (Santa Cruz, sc-47724). Primary antibodies were used at a dilution of 1:1000.
Luciferase activity assay
The Twist 3’-UTR luciferase vectors was obtained from OriGene (Rockville, MD, USA). A quick-change site-directed mutagenesis kit (Stratagene, CA, USA) was used to mutate the miR-548c-binding site. Luciferase activity was measured at 24 h after transfection using the dual-luciferase reporter assay system (Promega, WI, USA) as previously reported .
Benign and tumor tissues
50 pairs of primary EC and adjacent non-tumor endometrial tissues, 60 epithelial OC tissues and 20 normal epithelial ovarian tissues were collected in the China-Japan Union Hospital of Jilin University, China. This study was approved by the Ethics Committee of China-Japan Union Hospital of Jilin University and conducted according to the principles of the Declaration of Helsinki. The patients signed a written inform consent for the procedures in the study. Samples were snap-frozen immediately at –80 °C, and total RNA was isolated using TRIzol reagents.
Results are presented as mean ± s.e.m. from at least three independent experiments performed in triplicate. 2-tailed Student’s t-test was used for statistical analysis. P-values < 0.05 were defined as significant.
MiR-548c is downregulated in endometrial and ovarian cancer tissues and decreased miR-548c levels associates with worse prognosis in patients with endometrial cancer
Clinical characteristics of 60 ovarian cancer patients
32 (53.3 %)
28 (46.7 %)
19 (31.7 %)
41 (68.3 %)
24 (40.0 %)
36 (60.0 %)
40 (66.7 %)
20 (33.3 %)
To investigate whether the downregulation of miR-548c is related with prognosis of EC or OC patients, we used the SurvMicro web tool  to investigate the relationship between miR-548c levels and prognosis of cancer patients. The analysis of published data on EC and OC from The Cancer Genome Atlas (TCGA) revealed that the low expression levels of miR-548c were associated with very poor overall survival in EC patients compared with those patients whose ECs express a high level of miR-548c (Fig. 1e and f). Although our meta-analysis of OCs using TCGA data did not show a clear separation between high-risk OCs and low-risk OCs based on miR-548c expression (P = 0.425), OC patients whose tumors display low miR-548c expression tend to have shorter survival (Fig. 1g and h). Thus, these data uncover an association between the loss of miR-548c expression and poor survival of EC patients, and indicate that miR-548c repression might be important for EC/OC growth and progression.
MiR-548c inhibits proliferation, migration and invasion of EC and OC cells
To verify whether miR-548c affect the progression and metastasis of EC and OC, we evaluated the effect of either knockdown or overexpression of miR-548c on the migratory and invasive abilities of these cells. Transwell migration and invasion assays demonstrated that downregulation of miR-548c expression significantly promoted migration and invasion of RL95-2 and OVCAR3 cells (Fig. 2f and g). In contrast, transient overexpression of miR-548c in HEC-1 and SKOV-3 cells significantly impaired in vitro cell migration and invasion (Fig. 2f, g and h). Together, these data support that miR-548c acts as a tumor suppressors to inhibit tumor growth, migration and invasion in both EC and OC cells.
Twist is a direct target of MiR-548c in EC and OC cells
Because Twist was identified as a potential target of miR-548c (Fig. 3b), we speculated that Twist serves as a direct target of miR-548c. Our western blot analysis suggested that the introduction of anti-548c led to an increase in Twist protein level in RL95-2 cells, while pre-548c resulted in the opposite effects in HEC-1 and SKOV-3 cells (Fig. 3c). To test whether miR-548c repression is mediated through the predicted binding site, the reporter plasmid containing putative miR-548c responsive site was transfected with anti-548c or anti-ctr into RL95-2 cells. The downregulation of miR-548c enhanced Twist 3’-UTR luciferase reporter activity compared with the negative control (Fig. 3d, left), suggesting that miR-548c suppresses translation of Twist. To verify that miR-548c directly represses Twist on its 3’-UTR, we cotransfected pre-548c or pre-ctr with the Twist 3’-UTR reporter into HEC-1 and SKOV-3 cells. The ectopic expression of pre-548c caused a repression on luciferase activity as compared with pre-ctr (Fig. 3d, middle and right). To further evaluate the interaction between miR-548c and Twist 3’-UTR, we generated Twist 3’-UTR mutated for miR-548c binding site and performed the luciferase assays upon either miR-548c overexpression or knockdown. Mutant 3’-UTR reporter activity was resistant to the addition of anti-548c or pre-548c (Fig. 3d), confirming that Twist is a direct target of miR-548c, and binding of miR-548c to the 3’-UTR of Twist mRNA is sufficient to reduce Twist protein levels.
Twist binds the E-cadherin promoter and represses E-cadherin transcription, whereas directly activating N-cadherin expression [28, 29]. In addition, the EMT induction has been linked to the emergence of a cancer stem cell (CSC)-like phenotype . Consistent with this notion, sorted CD133+ EC cells have been shown to demonstrate greater tumor initiating capacity than CD133− cells , and CSC-like cells obtained from SKOV-3 cells express higher levels of CD133 . Matrix metalloproteinase 9 (MMP-9) is a downstream target of Twist in tumor cells . We test whether miR-548c regulates these genes in cancer cells used in this study. By using qPCR, we found a significant decrease in the expression of E-cadherin and an increased expression in N-cadherin, CD133 and MMP-9 levels in anti-548c-transfected RL95-2 cells (Fig. 3e). In contrast, miR-548c overexpression in HEC-1 and SKOV-3 cells significantly induced E-cadherin levels, but inhibited the expression of N-cadherin, CD133 and MMP-9 (Fig. 3e). Furthermore, we used qPCR to examine the mRNA expression of Twist in EC and OC tissues. As expected, Twist levels was markedly elevated in EC samples when compared to adjacent normal tissues (Fig. 1c). We also observed significantly increased Twist expression in OCs relative to normal ovarian tissues, and found higher levels of Twist in serous, advanced, high-grade ovarian cancers (Fig. 1d). Altogether, these data are consistent with our hypothesis that increased Twist expression in EC and OC is a functional consequence of miR-548c repression (at least in part).
Twist mediates miR-548c-reduced cancer cell migration and invasion
Targeting of metastasis-related miRNAs in human tumors may offer potential therapeutic strategies for these diseases [34, 35]. Recent findings have identified miR-548c family members as universe miRNA, and illustrated the possibility that these miRNAs exert broad effects on many features of tumor cells through a broad range of targets and pathways . Although one such miRNA, miR-548c, has been shown to inhibit cancer cell growth , its cellular functions, underlying mechanisms and clinical significance have not been comprehensively studied in gynecological cancers. Here, we found that miR-548c was under-expressed in both EC and OC samples, compared to their non-tumor counterparts. At the molecular level, miR-548c represses migration and invasion of EC and OC cells partially by targeting Twist. We demonstrate that miR-548c expression was inversely correlated with Twist level in EC and OC tissues, and reduced miR-548c expression was associated with poor prognosis in EC patients. These findings reveal for the first time that in EC and OC cells, miR-548c is a tumor-suppressive miRNA that inhibits multiple malignant features of the metastatic cascade.
Twist has been known as a novel oncogene overexpressed in diverse tumors , and activation of Twist inhibits apoptosis and promotes the induction of EMT, cancer stemness, proliferation, angiogenesis and vasculogenic mimicry in human tumor cells, all of which contributes to metastasis [37, 38]. Several upstream regulators and downstream effector of Twist have been reported , however our knowledge of the detailed molecular mechanisms involved in Twist overexpression, especially the epigenetic regulation of Twist expression, is still incomplete. Here, we reported a previously unidentified mechanism whereby loss of miR-548c expression is partially responsible for increased Twist levels in EC and OC, two of the most common gynecologic cancers.
Twist has been shown to upregulate the expression of some miRNAs, such as miR-10b  and miR-424 . Twist promotes the expression of miR-10b by directly binding to the promoter of miR-10b, which initiates tumor invasion and metastasis in breast cancer . Furthermore, miR-424, another miRNA that can be induced by Twist, drives EMT-like phenotypes in breast cancers . The impact of Twist on miR-548c expression in EC and OC cells warrants further investigation.
MiR-548c was reported to be an independent prognostic factor for breast cancer. Patients with a good prognosis presented higher intratumoral expression of miR-548c . Consistently, our meta-analysis suggested that high expression of miR-548c in EC and OC appears to correlate with better survival in patients with EC and OC, implying that miR-548c may be a new promising prognostic factor in these cancers. Since miR-548c directly regulates Twist in EC and OC cells, this miRNA might also represent an attractive target for the treatment of Twist-overexpressing tumors.
Our findings provide a novel mechanism by which the repression of miR-548c increases Twist levels to stimulate cancer cell migration and invasion of both EC and OC cells. Our results indicate that miR-548c is a potential therapeutic target in EC and OC.
We are grateful to the staff and patients at the Department of Obstetrics and Gynecology, China-Japan Union Hospital of Jilin University for providing the samples.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Dong P, Kaneuchi M, Konno Y, Watari H, Sudo S, Sakuragi N. Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int. 2013;2013:130362.PubMedPubMed CentralGoogle Scholar
- Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14.PubMedPubMed CentralView ArticleGoogle Scholar
- Bast Jr RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–28.PubMedPubMed CentralView ArticleGoogle Scholar
- Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–58.PubMedView ArticleGoogle Scholar
- Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59–66.PubMedView ArticleGoogle Scholar
- Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33:62.PubMedPubMed CentralView ArticleGoogle Scholar
- Wang WS, Yu SL, Yang XS, Chang SD, Hou JQ. Expression and significance of twist and E-cadherin in ovarian cancer tissues. Asian Pac J Cancer Prev. 2013;14:669–72.PubMedView ArticleGoogle Scholar
- Wang WS, Yang XS, Xia M, Jiang HY, Hou JQ. Silencing of twist expression by RNA interference suppresses epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer. Asian Pac J Cancer Prev. 2012;13:4435–9.PubMedView ArticleGoogle Scholar
- Kyo S, Sakaguchi J, Ohno S, Mizumoto Y, Maida Y, Hashimoto M, et al. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol. 2006;37:431–8.PubMedView ArticleGoogle Scholar
- Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, et al. Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol. 2009;42:82–91.PubMedView ArticleGoogle Scholar
- Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, et al. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer. 2007;96:314–20.PubMedPubMed CentralView ArticleGoogle Scholar
- Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15:546–54.PubMedPubMed CentralView ArticleGoogle Scholar
- Liu X, Chen X, Yu X, Tao Y, Bode AM, Dong Z, et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res. 2013;32:96.PubMedPubMed CentralView ArticleGoogle Scholar
- Katz B, Tropé CG, Reich R, Davidson B. MicroRNAs in ovarian cancer. Hum Pathol. 2015;46:1245–56.PubMedView ArticleGoogle Scholar
- Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N. MicroRNA-106b modulates epithelial–mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog. 2014;53:349–59.PubMedView ArticleGoogle Scholar
- Bing L, Hong C, Li-Xin S, Wei G. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet. 2014;290:533–41.PubMedView ArticleGoogle Scholar
- Shirdel EA, Xie W, Mak TW, Jurisica I. NAViGaTing the micronome--using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PLoS ONE. 2011;6:e17429.PubMedPubMed CentralView ArticleGoogle Scholar
- Piriyapongsa J, Jordan IK. A family of human microRNA genes from miniature inverted-repeat transposable elements. PLoS ONE. 2007;2, e203.PubMedPubMed CentralView ArticleGoogle Scholar
- Hu B, Ying X, Wang J, Piriyapongsa J, Jordan IK, Sheng J, et al. Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene. Cancer Res. 2014;74:2283–94.PubMedView ArticleGoogle Scholar
- Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, et al. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008;18:858–70.PubMedView ArticleGoogle Scholar
- Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70:10433–44.PubMedView ArticleGoogle Scholar
- Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 2009;9:20.PubMedPubMed CentralView ArticleGoogle Scholar
- Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer. 2011;10:99.PubMedPubMed CentralView ArticleGoogle Scholar
- Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2013;32:3286–95.PubMedPubMed CentralView ArticleGoogle Scholar
- Dong PX, Jia N, Xu ZJ, Liu YT, Li DJ, Feng YJ. Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro. J Exp Clin Cancer Res. 2008;27:7.View ArticleGoogle Scholar
- Aguirre-Gamboa R, Trevino V. SurvMicro: assessment of miRNA based prognostic signatures for cancer clinical outcomes by multivariate survival analysis. Bioinformatics. 2014;30:1630–2.PubMedView ArticleGoogle Scholar
- Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK, Lai LC, et al. miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS ONE. 2012;7:e42390.PubMedPubMed CentralView ArticleGoogle Scholar
- Vesuna F, van Diest P, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367:235–41.PubMedPubMed CentralView ArticleGoogle Scholar
- Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, Heimark RLAlexander NR, et al. N-cadherin Gene Expression in Prostate Carcinoma Is Modulated by Integrin-Dependent Nuclear Translocation of Twist1. Cancer Res. 2006;66:3365–9.PubMedView ArticleGoogle Scholar
- Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–51.PubMedPubMed CentralView ArticleGoogle Scholar
- Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol. 2010;41:1516–29.PubMedView ArticleGoogle Scholar
- Ma L, Lai D, Liu T, Cheng W, Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai). 2010;42:593–602.View ArticleGoogle Scholar
- Zhao XL, Sun T, Che N, Sun D, Zhao N, Dong XY, et al. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. J Cell Mol Med. 2011;15:691–700.PubMedPubMed CentralView ArticleGoogle Scholar
- Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, et al. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget. 2015;6:23323–41.PubMedView ArticleGoogle Scholar
- Luo G, Chao YL, Tang B, Li BS, Xiao YF, Xie R, et al. miR-149 represses metastasis of hepatocellular carcinoma by targeting actin-regulatory proteins PPM1F. Oncotarget. 2015;6:37808–23.PubMedGoogle Scholar
- Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277–9.PubMedView ArticleGoogle Scholar
- Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013;34:2497–506.PubMedView ArticleGoogle Scholar
- Jung HY, Yang J. Unraveling the TWIST between EMT and Cancer Stemness. Cell Stem Cell. 2015;16:1–2.PubMedView ArticleGoogle Scholar
- Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–8.PubMedView ArticleGoogle Scholar
- Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, et al. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Res. 2015;75(9):1908–21.PubMedView ArticleGoogle Scholar
- Boukerroucha M, Josse C, ElGuendi S, Boujemla B, Frères P, Marée R, et al. Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. BMC Cancer. 2015;15:755.PubMedPubMed CentralView ArticleGoogle Scholar